¹û¶³´«Ã½

James Halstead battles through tough markets

Cost cuts offset the damage of another year of falling sales

Investors should exit this litigation funder

Simon Thompson: A stream of case losses has led to a huge loss and sharply higher debt

Niox settles down after bid turbulence

The asthma and COPD testing specialist looks operationally solid in the wake of failed talks

Jadestone Energy’s new management has a lot to get right

Asian oil and gas is popular with investors more broadly, but the company has fumbled any momentum

Animalcare expands acquisition and new drug plans

The animal medicines specialist looks to secure its future by increasing R&D spending

Next 15 steps up simplification push after Mach49 blow

Excluding the crisis-hit agency, the wider group held margins steady despite softer revenues

This small cap is gaining real momentum

Simon Thompson: Bulk sales of its patented product are scaling up, and it is in talks with several new customers

A venture capital fund on a tantalising discount

Simon Thompson: Sum-of-the-parts valuation is only three times the share price

Time to switch out of this manufacturer

Simon Thompson: Political and economic uncertainty is tempering orders and a debt refinancing has been put on hold

Is this lithium miner worth holding?

Simon Thompson: The company has raised £7.5mn from investors this year to help progress its flagship project